1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Research and Forecast on China Insulin Market, 2014-2018

Research and Forecast on China Insulin Market, 2014-2018

  • April 2014
  • -
  • Huidian Research
  • -
  • 65 pages

Research and Forecast on China Insulin Market, 2014-2018 carries on a thorough analysis of development history, policy environment, import and export, new products and key enterprises of China Insulin Market.

A survey conducted by Huidian Research shows that China’s insulin market scale approximately registered CNY 11 billion in 2013, of which CNY 7.5 billion achieved in second-generation insulin market and CNY 3.5 billion generated in third-generation insulin market. Now third-generation insulin market grows faster than second-generation insulin. And second-generation insulin market will accelerate growing space because it is just listed into new essential drug catalogue.

Currently there are only two companies owning full series of insulin products globally, Tonghua Dongbao is one of the two. As for global insulin market at present, only three companies, including Tonghua Dongbao, Novo Nordisk and Eli Lilly, produce second-generation insulin in quantity. Under oligopolistic competition in the global market, it is difficult to tell which companies’ products are better, but Tonghua Dongbao enjoys the lowest overall production cost. Compared with expensive insulin produced by transnational giants, governments can reduce expenditure of health insurance if buying Dongbao’s insulin, so Tonghua Dongbao will become a powerful contender when competing for more market shares with transnational giants in the developing countries.

Four domestic companies obtained production approval of second-generation insulin, namely United Laboratories, Donghua Tongbao, Wanbang and Shenzhen Kexing Biotech. The latter two received production approval in 2003, but their products did not sell in market due to bad quality. Currently Wanbang’s animal insulin injections enjoy the largest sales volume in China.

Third-generation insulin in foreign market covers rapid-acting insulin (insulin aspart and insulin lispro) and long-acting insulin (insulin glargine and insulin detemir). Recombinant insulin lispro and its injection, which are high-end products, also belong to third-generation insulin. Third-generation insulin is quicker to take effects and also can better simulate physiologic insulin secretion pattern. Information disclosed by China Food and Drug Administration show that Eli Lilly and Company and Gan & Lee (a private company in China) owns production approval documents of this type of insulin. Affected by its commercial bribery case, business performance of Gan & Lee witnessed a significant drop in 2013, but its third-generation insulin that is a foreign-funded brand with dominant position in market had not been influenced much.

Huidian Research holds a view that for now third-generation insulin is superior in effects but its price is far higher than second-generation insulin, so low and middle income patients without medical insurance are hard to pay for the expensive drug cost. So in wide grass roots market, second-generation insulin enjoys an overwhelming superiority. But it is predicated that with the decreasing price, third-generation insulin will replace second-generation insulin in the next years, representing the general trend.

Please note: The report is Chinese version. It will provide the English version in two business days.

Table Of Contents

Research and Forecast on China Insulin Market, 2014-2018
1. Overview of Insulin
1.1 Brief Introduction to Diabetes and General Situation of Related Therapeutic Drugs
1.1.1 Overview of Diabetes
1.1.2 Clinical Classification of Diabetes
1.1.3 Major Therapeutic Drugs, Clinical Effects and Treatment Strategy
1.2 Definition and Classification of Insulin
1.2.1 Definition
1.2.2 Classification
1.3 Development History of Insulin in China
1.3.1 First-Generation Insulin (Multi-component Insulin Extracted from Animal Pancreas)
1.3.2 Second-Generation Insulin (Insulin Human)
1.3.3 Third-Generation Insulin (Improved Insulin or Insulin Analogues)

2. Operation Environment of China Insulin Market in 2013
2.1 China's Economic Environment in 2013
2.2 Policy Environment in 2013
2.2.1 Opinions Concerning Deepening Medical and Health System Reform
2.2.2 Planning and Implementation of Deepening Medical and Health System Reform During the 12th Five-Year Plan
2.2.3 Comprehensive Improved Standards for Insulin and Recombinant Human Insulin in Chinese Pharmacopoeia 2010
2.2.4 Educational Management Standards for Using Insulin
2.2.5 Prevention Guideline of Type 2 Diabetes Mellitus in 2013
2.2.6 Continuous Anti-corruption in Medicine
2.3 Technological Environment in 2013
2.3.1 Insulin Pump
2.3.2 Diabetes Treatment by Using Stem Cell Transplantation is on Clinical Test Stage
2.4 Chinese Consumers' Cognition toward Insulin

3. Trend of China Insulin Market in 2013
3.1 Current Situation
3.1.1 Development Status of Diabetes in China and at Overseas
3.1.2 Market Scale
3.2 New Pattern of China Insulin Industry in 2013

4. Import and Export Data of Product Segments of Insulin in China, 2011-2013
4.1 Import and Export Data of Insulin and Its Salt in China, 2011-2013 (HS Code: 293712)
4.2 Export Data of Drugs Containing Insulin without Defined Daily Doses, 2011-2013 (HS Code: 300331)
4.3 Import and Export Data of Drugs Containing Insulin with Defined Daily Doses, 2011-2013 (HS Code: 300431)

5. Key Enterprises in Insulin Industry
5.1 Tonghua Dongbao
5.1.1 Company Profile
5.1.2 Business Performance
5.1.3 Main Business Composition
5.1.4 Progress of Research and Development
5.1.5 Channel Expansion
5.1.6 Development Plan in 2014
5.2 Wanbang Biopharmaceuticals
5.2.1 Company Profile
5.2.2 Business Performance
5.2.3 Third-Generation Insulin Approved to be used in Clinical Test
5.2.4 Marketing Network
5.2.5 Growth Pattern in the Next Five Years
5.3 United Laboratories
5.3.1 Company Profile
5.3.2 Business Performance
5.3.3 Production Capacity
5.3.4 New Products
5.3.5 Marketing Promotion Channel
5.3.6 Future Development Strategy
5.4 Gan and Lee
5.4.1 Company Profile
5.4.2 Business Performance
5.4.3 Commercial Bribery Case
5.4.4 Business Channel Expands to County-level Central Hospitals
5.5 Yabao Pharmaceutical Group
5.5.1 Company Profile
5.5.2 Channel Building
5.5.3 Research and Development
5.6 Novo Nordisk
5.6.1 Company Profile
5.6.2 Business Performance
5.6.3 Enterprise RandD
5.7 Eli Lilly and Company
5.7.1 Company Profile
5.7.2 Progress of RandD
5.7.3 Overall Increase of Insulin Production Capacity in China
5.7.4 Business Condition
5.7.5 Channel Expansion
5.8 SANOFI
5.8.1 Company Profile
5.8.2 RandD Framework
5.8.3 Enterprise Operation

6. Development Trend and Prospect Forecast of China Insulin Market, 2014-2018
6.1 Development Prospect
6.1.1 Enormous Insulin Market Potential
6.1.2 Huge Oral Insulin Market Potential
6.2 Development Trend
6.2.1 Opportunities and Challenges for Enterprise RandD brought by Policy Environment Change
6.2.2 Development Trend of Insulin Products
6.3 China Insulin Market Forecast from 2014 to 2018


Companies Mentioned

Tonghua Dongbao
Wanbang Biopharmaceuticals
United Laboratories
Gan and Lee
Yabao Pharmaceutical Group
Novo Nordisk
Eli Lilly and Company
SANOFI

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Type 2 Diabetes Mellitus: KOL Insight 2016

Type 2 Diabetes Mellitus: KOL Insight 2016

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Can top-ranked GLP1 agonists move out of the third-line setting? GLP1 agonists may be the top-ranked type 2 diabetes mellitus (T2DM) treatment according to the American Association of Clinical Endocrinologists ...

European Market Report for Modern Insulin 2016 - MedCore

European Market Report for Modern Insulin 2016 - MedCore

  • $ 5995
  • Industry report
  • September 2016
  • by iData Research, Inc.

The European modern insulin market can be segmented by insulin type, yielding three segments: long-acting insulin, rapid-acting insulin and premixed insulin. In 2015, the largest segment in the total modern ...

US Market Report for Insulin 2017 - MedCore

US Market Report for Insulin 2017 - MedCore

  • $ 5495
  • Industry report
  • November 2016
  • by iData Research, Inc.

Description The U.S. insulin market can be segmented by insulin type, yielding four segments: long-acting insulin, rapid-acting insulin, premixed insulin and human insulin. In 2016, the largest segment ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in New Zealand - Forecast

  • December 2016
    71 pages
  • Therapy  

  • New Zealand  

View report >

Insulin Market in the US

  • December 2016
    8 pages
  • Insulin  

  • United States  

View report >

Therapy Market in the UK

  • December 2016
    194 pages
  • Therapy  

    Infectious Dise...  

    Eye Disease  

  • United Kingdom  

View report >

Related Market Segments :

Insulin
Pharmaceutical
Diabetes

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.